OXYRASE, A METHOD WHICH AVOIDS CO2 IN THE INCUBATION ATMOSPHERE FOR ANAEROBIC SUSCEPTIBILITY TESTING OF ANTIBIOTICS AFFECTED BY CO2

被引:19
作者
SPANGLER, SK [1 ]
APPELBAUM, PC [1 ]
机构
[1] PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT PATHOL CLIN MICROBIOL,HERSHEY,PA 17033
关键词
D O I
10.1128/JCM.31.2.460-462.1993
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Oxyrase agar dilution method, with exclusion of CO2 from the environment, was compared with the reference agar dilution method recommended by the National Committee for Clinical Laboratory Standards (anaerobic chamber with 10% CO2) to test the susceptibility of 51 gram-negative and 43 gram-positive anaerobes to azithromycin and erythromycin. With the Oxyrase method, anaerobiosis was achieved by incorporation of the O2-binding enzyme Oxyrase in addition to susceptibility test medium, antibiotic, and enzyme substrates into the upper level of a biplate. Plates were covered with a Brewer lid and incubated in ambient air. With azithromycin, Oxyrase yielded an MIC for 50% of strains tested (MIC50) and MIC90 of 2.0 and 8.0 mug/ml, compared to 8.0 and >32.0 mug/ml in standard anaerobic conditions. At a breakpoint of 8.0 mug/ml, 90.4% of strains were susceptible to azithromycin with Oxyrase, compared to 53.2% in the chamber. The corresponding erythromycin MIC50 and MIC90 were 1.0 and 8.0 mug/ml with Oxyrase, compared to 4.0 and >32.0 mug/ml by the reference method, with 89.3% of strains susceptible at a breakpoint of 4 mug/ml with Oxyrase, compared to 60.6% in CO2. Exclusion of CO2 from the anaerobic atmosphere when testing for susceptibility to azalides and macrolides yielded lower MICs, which may lead to a reconsideration of the role played by these compounds in treatment of infections caused by these strains.
引用
收藏
页码:460 / 462
页数:3
相关论文
共 16 条
[1]   INVITRO POTENCY OF AZITHROMYCIN AGAINST GRAM-NEGATIVE BACILLI IS METHOD-DEPENDENT [J].
BARRY, AL ;
FUCHS, PC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 (04) :607-610
[2]  
COPELAND J, 1991, COMMUNICATION
[3]   THE PHARMACOKINETICS OF AZITHROMYCIN IN HUMAN SERUM AND TISSUES [J].
FOULDS, G ;
SHEPARD, RM ;
JOHNSON, RB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 :73-82
[4]   CORRELATION OF THE EXTRAVASCULAR PHARMACOKINETICS OF AZITHROMYCIN WITH INVIVO EFFICACY IN MODELS OF LOCALIZED INFECTION [J].
GIRARD, AE ;
GIRARD, D ;
RETSEMA, JA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 :61-71
[5]   PHARMACOKINETIC AND INVIVO STUDIES WITH AZITHROMYCIN (CP-62,993), A NEW MACROLIDE WITH AN EXTENDED HALF-LIFE AND EXCELLENT TISSUE DISTRIBUTION [J].
GIRARD, AE ;
GIRARD, D ;
ENGLISH, AR ;
GOOTZ, TD ;
CIMOCHOWSKI, CR ;
FAIELLA, JA ;
HASKELL, SL ;
RETSEMA, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (12) :1948-1954
[6]   EFFECT OF CARBON-DIOXIDE AND PH ON SUSCEPTIBILITY OF BACTEROIDES-FRAGILIS GROUP TO ERYTHROMYCIN [J].
HANSEN, SL ;
SWOMLEY, P ;
DRUSANO, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 19 (02) :335-336
[7]   INVITRO ACTIVITY OF AZITHROMYCIN AGAINST VARIOUS GRAM-NEGATIVE BACILLI AND ANAEROBIC-BACTERIA [J].
KITZIS, MD ;
GOLDSTEIN, FW ;
MIEGI, M ;
ACAR, JF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 :15-18
[8]  
NACHNANI S, 1992, 92ND GEN M AM SOC MI, P3
[9]  
PONTICAS S, 1989, 29TH INT C ANT AG CH
[10]  
PRATT K, 1992, 92 GEN M AM SOC MICR, P481